Latest Breaking News On - Transplant immunology - Page 4 : comparemela.com

Vera Therapeutics (VERA) Presents New Analysis of Phase 2a JANUS Trial of Atacicept, Reports Positive Final Phase 2 Results of MAU868

Vera Therapeutics (VERA) Presents New Analysis of Phase 2a JANUS Trial of Atacicept, Reports Positive Final Phase 2 Results of MAU868
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesCelia linLos angelesJoyce allaire lifesciJonathan barrattUniversity of leicesterAmplyx pharmaceuticals incSinai medical centerVera therapeutics incKathy vincentgreig communications incExchange commissionPfizer incAmerican society of nephrologyEuropean unionAmerican society of nephrology kidney weekAmerican society

Vera Therapeutics Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection at the American Society of Nephrology Kidney Week 2022 Annual Meeting

Vera Therapeutics Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection at the American Society of Nephrology Kidney Week 2022 Annual Meeting
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United statesCelia linLos angelesKathy vincentJoyce allaireJonathan barrattUniversity of leicesterAmplyx pharmaceuticals incSinai medical centerGreig communications incVera therapeutics incExchange commissionPfizer incAmerican society of nephrologyEuropean unionAmerican society of nephrology kidney week

Vera Therapeutics Presents New Analysis of Phase 2a JANUS

New analysis of Phase 2a JANUS clinical trial showed atacicept reduced immune complex levels in patients with IgA nephropathy (IgAN)Atacicept is the first.

United statesCelia linLos angelesKathy vincentJoyce allaireJonathan barrattUniversity of leicesterAmplyx pharmaceuticals incSinai medical centerGreig communications incVera therapeutics incExchange commissionPfizer incAmerican society of nephrologyEuropean unionAmerican society of nephrology kidney week

Vera Therapeutics to Present Final Phase 2 Results of

BRISBANE, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and.

United statesOrange county convention centerLos angelesKathy vincentJoyce allaireJonathan barrattUniversity of leicesterAmplyx pharmaceuticals incSinai medical centerGreig communications incVera therapeutics incExchange commissionPfizer incAmerican society of nephrology kidney weekAmerican societyNephrology kidney week

Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2022 Annual Meeting

BRISBANE, Calif., Oct. 17, 2022 Vera Therapeutics, Inc. , a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious. | October 17, 2022

United statesOrange county convention centerLos angelesJoyce allaireJonathan barrattUniversity of leicesterAmplyx pharmaceuticals incSinai medical centerVera therapeutics incExchange commissionPfizer incAmerican society of nephrology kidney weekAmerican societyNephrology kidney weekRandomized phaseKidney transplant